1. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial;Huh;Lancet,2017
2. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women;Joura;N Engl J Med,2015
3. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions;Serrano;Eur J Cancer,2015
4. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide;Alemany;Int J Cancer,2015
5. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunisation practices;Petrosky;MMWR Morb Mortal Wkly Rep,2015